Dacoregio, Maria Inez Michelon, Isabella Ernesto do Rego Castro, Caio Cezar Aquino de Moraes, Francisco Rossato de Almeida, Guilherme Ravani, Lis Victória Vilbert, Maysa Barros Costa, Ricardo Lima
Published in
Breast (Edinburgh, Scotland)
Sacituzumab Govitecan (SG), a first-in-class anti-trophoblast cell surface antigen-2-directed antibody-drug conjugate (ADC), has shown clinically meaningful improvement in outcomes of patients with breast cancer (BC). However, it has also been accompanied by significant toxicity. Thus, we conducted a systematic review and meta-analysis to evaluate ...
Rugo, Hope S Schmid, Peter Tolaney, Sara M Dalenc, Florence Marmé, Frederik Shi, Ling Verret, Wendy Shah, Anuj Gharaibeh, Mahdi Bardia, Aditya
...
Published in
The oncologist
The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physician's choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related quality of li...
Rugo, Hope Schmid, Peter Tolaney, Sara Dalenc, Florence Marmé, Frederik Shi, Ling Verret, Wendy Shah, Anuj Gharaibeh, Mahdi Bardia, Aditya
...
BACKGROUND: The TROPiCS-02 study (NCT03901339) demonstrated that sacituzumab govitecan (SG) has superior clinical outcomes over treatment of physicians choice (TPC) chemotherapy in patients with hormone receptor-positive, human epidermal growth factor 2 receptor-negative (HR+/HER2-) metastatic breast cancer (mBC). Here, we present health-related qu...
Bartsch, Rupert Rinnerthaler, Gabriel Petru, Edgar Egle, Daniel Gnant, Michael Balic, Marija Sliwa, Thamer Singer, Christian
Published in
Wiener klinische Wochenschrift
Approximately 15% of newly diagnosed breast cancer patients have neither hormone receptors expression nor HER2 overexpression and/or HER2/neu gene amplification. This subtype of breast cancer is known as Triple Negative Breast Cancer (TNBC), and carries a significantly elevated risk of local and distant recurrence. In comparison with other breast c...
Wu, Yilai Hu, Shanshan Liu, Xiaolin Chen, Yang Luan, Jiajie Wang, Shuowen
Published in
Cost Effectiveness and Resource Allocation : C/E
Background Sacituzumab govitecan (SG) has recently been approved in China for the post-line treatment of metastatic triple-negative breast cancer (mTNBC). SG substantially improves progression-free survival and overall survival compared with single-agent chemotherapy for pretreated mTNBC. However, in view of the high price of SG, it is necessary to...
Schlam, Ilana Chavez-MacGregor, Mariana
Published in
Breast (Edinburgh, Scotland)
Caputo, Roberta Buono, Giuseppe Piezzo, Michela Martinelli, Claudia Cianniello, Daniela Rizzo, Alessandro Pantano, Francesco Staropoli, Nicoletta Cangiano, Rodolfo Turano, Salvatore
...
Published in
Frontiers in Oncology
Objective The objective of this multicenter, observational, retrospective analysis was to evaluate the safety and efficacy of sacituzumab govitecan in metastatic triple-negative breast cancer (mTNBC) patients managed according to common clinical practice in Italy. Methods Data were retrieved by 7 sites. Triple-negative BC was defined by the lack of...
Kathpalia, Meghavi Sharma, Anurag Kaur, Navkiran
Published in
The Annals of pharmacotherapy
Chemotherapy, the only treatment option for metastatic triple-negative breast cancer (mTNBC), showed decreased survival rates. Trophoblast cell surface antigen-2 (Trop-2) could be a possible target for antibody-drug conjugates (ADCs). Sacituzumab govitecan (SG), an anti-Trop-2 ADC for pretreating relapsed/refractory mTNBC patients, was studied to k...
de Moura, Alexandre Loirat, Delphine Korbi, Sinen Kiavue, Nicolas Bello Roufai, Diana Vaflard, Pauline Cottu, Paul Pierga, Jean Yves Bidard, François Clément Cabel, Luc
...
© The Author(s) 2024.Background: Sacituzumab govitecan (SG) has been approved by FDA in April 2021 for pre-treated metastatic triple-negative breast cancer (mTNBC), following the ASCENT trial results. Methods: We set up an ambispective bicentric cohort study to assess the real-world effectiveness and safety of SG in patients with mTNBC treated at I...
Mertens, Richard B Makhoul, Elias P Li, Xiaomo Dadmanesh, Farnaz
Published in
Annals of diagnostic pathology
Sacituzumab govitecan, targeting trophoblast cell-surface antigen 2 (TROP2), is approved for the treatment of triple-negative and hormone receptor-positive/HER2-negative breast cancers. However, detailed studies comparing TROP2 protein expression in the different molecular subtypes of breast cancer are limited, and definitive evidence supporting th...
